The U.S. Food and Drug Administration (FDA) and Zynerba Pharmaceuticals will meet later this year to discuss…
Articles by Patricia Inácio, PhD
Shortage of energy due to leaky mitochondria — the powerhouses of cells — contributes to behavioral abnormalities in…
Measuring the levels of three blood biomarkers could help identify patients with fragile X syndrome who are likely to benefit from…
A parent language intervention based on story-telling eases the severity of speech and social impairments in children with fragile…
Poorer health-related quality of life (HRQoL) correlate with greater emotional, behavioral, and school problems in children with fragile X…
Genetic testing for fragile X syndrome (FXS) should be reserved as a second-line strategy for people without clinical features…
Zynerba Pharmaceuticals has completed enrollment for the CONNECT-FX trial testing its cannabidiol gel, Zygel, as a treatment…
A Phase 2/3 trial testing the cannabidiol gel Zygel as a treatment for behavioral symptoms in…
Increasing the levels of the SOD2 protein in mitochondria — the powerhouses of cells — may help halt…
The CONNECT-FX trial testing the cannabidiol (CBD) gel Zygel as a treatment for behavioral symptoms in children and teenagers…